Literature DB >> 32646918

The associations of interstitial lung abnormalities with cancer diagnoses and mortality.

Gisli T Axelsson1, Rachel K Putman2, Thor Aspelund3,4, Elias F Gudmundsson4, Tomayuki Hida5,6, Tetsuro Araki5,6, Mizuki Nishino5,6, Hiroto Hatabu5,6, Vilmundur Gudnason3,4, Gary M Hunninghake2,6, Gunnar Gudmundsson3,7.   

Abstract

An increased incidence of lung cancer is well known among patients with idiopathic pulmonary fibrosis. It is not known whether interstitial lung abnormalities, i.e. early fibrotic changes of the lung, are a risk factor for lung cancer in the general population.The study's objective was to assess whether interstitial lung abnormalities were associated with diagnoses of, and mortality from, lung cancer and other cancers. Data from the AGES-Reykjavik study, a cohort of 5764 older Icelandic adults, were used. Outcome data were ascertained from electronic medical records. Gray's tests, Cox proportional hazards models and proportional subdistribution hazards models were used to analyse associations of interstitial lung abnormalities with lung cancer diagnoses and lung cancer mortality as well as diagnoses and mortality from all cancers.There was a greater cumulative incidence of lung cancer diagnoses (p<0.001) and lung cancer mortality (p<0.001) in participants with interstitial lung abnormalities than in others. Interstitial lung abnormalities were associated with an increased hazard of lung cancer diagnosis (hazard ratio 2.77) and lung cancer mortality (hazard ratio 2.89) in adjusted Cox models. Associations of interstitial lung abnormalities with all cancers were found in models including lung cancers but not in models excluding lung cancers.People with interstitial lung abnormalities are at increased risk of lung cancer and lung cancer mortality, but not of other cancers. This implies that an association between fibrotic and neoplastic diseases of the lung exists from the early stages of lung fibrosis and suggests that interstitial lung abnormalities could be considered as a risk factor in lung cancer screening efforts.
Copyright ©ERS 2020.

Entities:  

Mesh:

Year:  2020        PMID: 32646918      PMCID: PMC7876778          DOI: 10.1183/13993003.02154-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  27 in total

1.  Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.

Authors:  Mizuki Nishino; Stephanie Cardarella; Suzanne E Dahlberg; Tetsuro Araki; Christine Lydon; David M Jackman; Michael S Rabin; Hiroto Hatabu; Bruce E Johnson
Journal:  Eur J Radiol       Date:  2015-02-07       Impact factor: 3.528

Review 2.  Idiopathic pulmonary fibrosis: Clinical behavior and aging associated comorbidities.

Authors:  Ivette Buendía-Roldán; Mayra Mejía; Carmen Navarro; Moisés Selman
Journal:  Respir Med       Date:  2017-06-03       Impact factor: 3.415

3.  Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality.

Authors:  Rachel K Putman; Gunnar Gudmundsson; Gisli Thor Axelsson; Tomoyuki Hida; Osamu Honda; Tetsuro Araki; Masahiro Yanagawa; Mizuki Nishino; Ezra R Miller; Gudny Eiriksdottir; Elías F Gudmundsson; Noriyuki Tomiyama; Hiroshi Honda; Ivan O Rosas; George R Washko; Michael H Cho; David A Schwartz; Vilmundur Gudnason; Hiroto Hatabu; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2019-07-15       Impact factor: 21.405

4.  Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections.

Authors:  Ezra R Miller; Rachel K Putman; Marina Vivero; Yin Hung; Tetsuro Araki; Mizuki Nishino; George R Washko; Ivan O Rosas; Hiroto Hatabu; Lynette M Sholl; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2018-04-01       Impact factor: 21.405

5.  Interstitial Lung Abnormalities and Lung Cancer Risk in the National Lung Screening Trial.

Authors:  Stacey-Ann Whittaker Brown; Maria Padilla; Grace Mhango; Charles Powell; Mary Salvatore; Claudia Henschke; David Yankelevitz; Keith Sigel; Juan P de-Torres; Juan Wisnivesky
Journal:  Chest       Date:  2019-08-09       Impact factor: 9.410

6.  The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK.

Authors:  Ivan Le Jeune; Jonathan Gribbin; Joe West; Chris Smith; Paul Cullinan; Richard Hubbard
Journal:  Respir Med       Date:  2007-09-17       Impact factor: 3.415

7.  Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer.

Authors:  Yongyu Wang; Phillip J Kuan; Chao Xing; Jennifer T Cronkhite; Fernando Torres; Randall L Rosenblatt; J Michael DiMaio; Lisa N Kinch; Nick V Grishin; Christine Kim Garcia
Journal:  Am J Hum Genet       Date:  2008-12-18       Impact factor: 11.025

8.  Association Between Interstitial Lung Abnormalities and All-Cause Mortality.

Authors:  Rachel K Putman; Hiroto Hatabu; Tetsuro Araki; Gunnar Gudmundsson; Wei Gao; Mizuki Nishino; Yuka Okajima; Josée Dupuis; Jeanne C Latourelle; Michael H Cho; Souheil El-Chemaly; Harvey O Coxson; Bartolome R Celli; Isis E Fernandez; Oscar E Zazueta; James C Ross; Rola Harmouche; Raúl San José Estépar; Alejandro A Diaz; Sigurdur Sigurdsson; Elías F Gudmundsson; Gudny Eiríksdottír; Thor Aspelund; Matthew J Budoff; Gregory L Kinney; John E Hokanson; Michelle C Williams; John T Murchison; William MacNee; Udo Hoffmann; Christopher J O'Donnell; Lenore J Launer; Tamara B Harrris; Vilmundur Gudnason; Edwin K Silverman; George T O'Connor; George R Washko; Ivan O Rosas; Gary M Hunninghake
Journal:  JAMA       Date:  2016-02-16       Impact factor: 56.272

9.  Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study.

Authors:  Tetsuro Araki; Rachel K Putman; Hiroto Hatabu; Wei Gao; Josée Dupuis; Jeanne C Latourelle; Mizuki Nishino; Oscar E Zazueta; Sila Kurugol; James C Ross; Raúl San José Estépar; David A Schwartz; Ivan O Rosas; George R Washko; George T O'Connor; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2016-12-15       Impact factor: 21.405

10.  Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis.

Authors:  Brian D Hobbs; Rachel K Putman; Tetsuro Araki; Mizuki Nishino; Gunnar Gudmundsson; Vilmundur Gudnason; Gudny Eiriksdottir; Nuno Rodrigues Zilhao Nogueira; Josée Dupuis; Hanfei Xu; George T O'Connor; Ani Manichaikul; Jennifer Nguyen; Anna J Podolanczuk; Purnema Madahar; Jerome I Rotter; David J Lederer; R Graham Barr; Stephen S Rich; Elizabeth J Ampleford; Victor E Ortega; Stephen P Peters; Wanda K O'Neal; John D Newell; Eugene R Bleecker; Deborah A Meyers; Richard J Allen; Justin M Oldham; Shwu-Fan Ma; Imre Noth; R Gisli Jenkins; Toby M Maher; Richard B Hubbard; Louise V Wain; Tasha E Fingerlin; David A Schwartz; George R Washko; Ivan O Rosas; Edwin K Silverman; Hiroto Hatabu; Michael H Cho; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2019-12-01       Impact factor: 21.405

View more
  4 in total

1.  Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients.

Authors:  Jeffrey A Sparks; Yinzhu Jin; Soo-Kyung Cho; Seanna Vine; Rishi Desai; Tracy J Doyle; Seoyoung C Kim
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

Review 2.  Clinical Relevance and Management of "Pre-Interstitial Lung Disease".

Authors:  Anna J Podolanczuk; Rachel K Putman
Journal:  Clin Chest Med       Date:  2021-06       Impact factor: 4.967

3.  Relationship between Incidental Abnormalities on Screening Thoracic Computed Tomography and Mortality: A Long-Term Follow-Up Analysis.

Authors:  Jong Eun Lee; Won Gi Jeong; Hyo-Jae Lee; Yun-Hyeon Kim; Kum Ju Chae; Yeon Joo Jeong
Journal:  Korean J Radiol       Date:  2022-10       Impact factor: 7.109

Review 4.  Interstitial Lung Abnormalities: State of the Art.

Authors:  Akinori Hata; Mark L Schiebler; David A Lynch; Hiroto Hatabu
Journal:  Radiology       Date:  2021-08-10       Impact factor: 29.146

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.